RAPT Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of 20.83%. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Johnson & Johnson's return on equity of 34.46%.

Rapt Therapeutics, Inc. has a consensus price target of $58.00, signalling upside risk potential of 0.49%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.01%. Given that Rapt Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Rapt Therapeutics, Inc. is more attractive than Johnson & Johnson.

Rapt Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.241% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Rapt Therapeutics, Inc.'s net income of -$17.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus 6.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of 18.06%. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Merck & Co., Inc.'s return on equity of 39.63%.

Rapt Therapeutics, Inc. has a consensus price target of $58.00, signalling upside risk potential of 0.49%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Merck & Co., Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Rapt Therapeutics, Inc..

Rapt Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.241% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Rapt Therapeutics, Inc.'s net income of -$17.6M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Penumbra, Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of 12.93%. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Penumbra, Inc.'s return on equity of 13.4%.

Rapt Therapeutics, Inc. has a consensus price target of $58.00, signalling upside risk potential of 0.49%. On the other hand Penumbra, Inc. has an analysts' consensus of $348.53 which suggests that it could grow by 2.72%. Given that Penumbra, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Penumbra, Inc. is more attractive than Rapt Therapeutics, Inc..

Rapt Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.241% less volatile than S&P 500. In comparison Penumbra, Inc. has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.405%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Penumbra, Inc. pays out -- of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Penumbra, Inc. quarterly revenues of $354.7M. Rapt Therapeutics, Inc.'s net income of -$17.6M is lower than Penumbra, Inc.'s net income of $45.9M. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Penumbra, Inc.'s PE ratio is 81.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus 9.97x for Penumbra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Rapt Therapeutics, Inc.'s net margin of -9.34%. Rapt Therapeutics, Inc.'s return on equity of -67.79% beat Pfizer Inc.'s return on equity of 10.84%.

Rapt Therapeutics, Inc. has a consensus price target of $58.00, signalling upside risk potential of 0.49%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.8%. Given that Pfizer Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Rapt Therapeutics, Inc..

Rapt Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.241% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Rapt Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.24% to investors and pays a quarterly dividend of $0.43 per share. Rapt Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Rapt Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Rapt Therapeutics, Inc.'s net income of -$17.6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Rapt Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapt Therapeutics, Inc. is 54.16x versus 2.51x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.